Surge In Lung Disease Prevalence Fuels Momentum In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Strengthening the Growth Trajectory of the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Through 2025?
The market size of treatments for chronic obstructive pulmonary disease (COPD) has seen consistent growth over the past years and is predicted to expand from $20.84 billion in 2024 to $21.73 billion in 2025 with a compound annual growth rate (CAGR) of 4.3%. This growth during the historical era can be associated with factors such as the widespread prevalence of smoking and tobacco use, advancements in inhalation therapies, early detection and awareness initiatives, government measures for respiratory health, and research and development in the field of pulmonology.

What's the Projected Size of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by 2029?
In the coming years, the market size for treatment of chronic obstructive pulmonary disease (COPD) is anticipated to witness substantial growth, aiming to reach $27.22 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 5.8%. This predicted growth during the forecast period is primarily attributable to factors such as customized medicine and biomarker study, focused interventions and biologic therapies, issues regarding air quality and environmental impacts, worldwide initiatives for smoking cessation, and alliances for drug advancement. Looking ahead, significant trends include the advent of digital health solutions for managing COPD, the development of biologic therapies specifically tailored for COPD patients, the rise of personalized medicine, compounds therapies and inhalers, early detection and immediate intervention, as well as pulmonary rehab programs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Top Growth Drivers in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry: What's Accelerating the Market?
The surge in lung disease occurrences is anticipated to spur the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease, a condition impairing the normal operation of lungs, is most frequently seen in forms such as asthma, COPD, and lung cancer. Primarily, the treatment of COPD is utilized to manage lung diseases, curb its advancement, regulate symptoms, and avert lung damage utilizing inhalers and medication. To illustrate, the global initiative for Chronic obstructive lung disease (GOLD), a non-profit organization based in the US, noted in September 2022 that COPD leads to 3.2 million deaths annually and affects nearly 200 million individuals. Additionally, it was identified that asthma impacted 262 million people across the globe in 2022. These figures are likely to escalate in the future. Furthermore, as per the LUNGevity Foundation, another US-based non-profit organization, lung cancer will cause the death of 127,000 Americans each year by 2023. Hence, the escalating prevalence of lung diseases is catalyzing the growth of the chronic obstructive pulmonary disease (COPD) treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp

What Are the Key Trends Driving Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth?
The chronic obstructive pulmonary disease (COPD) treatment market is increasingly gravitating towards product innovation. Major firms involved in the COPD treatment market have been busily producing innovative solutions to maintain their standing. In the year 2022, April specifically, GlaxoSmithKline plc (GSK), a pharmaceutical and biotech company based in the UK, introduced Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) to the Indian market. This was the first single-inhaler triple treatment (SITT) designed for COPD patients in India. Trelegy Ellipta serves as a maintenance drug, treating and preventing COPD symptoms in individuals aged 18 and above. Mimicking the functions of natural corticosteroid hormones, it suppresses immune system activity by binding to receptors on specific immune cells. It also aids in reducing the lung airway inflammation, thereby easing breathing.

What Are the Main Segments in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented -

1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp

Which Top Companies are Driving Growth in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.

Which Regions Will Dominate the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Through 2029?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10054

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.